Search
Home
News
Fortune 500
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Great Place To Work
Tech
AI
Innovation
Cybersecurity
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Success
Future Of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Analytics
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Home
News
Fortune 500
Fortune 500
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Great Place To Work
Tech
Tech
AI
Innovation
Cybersecurity
Finance
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Leadership
Success
Future Of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Rankings
Analytics
Multimedia
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Asia
Europe
Analytics
Laura Lorenzetti
Stay informed with Laura Lorenzetti’s coverage and analysis for Fortune.
Page 73 of 73
Kindred offers $533 million to buy Atlanta healthcare rival
By
Laura Lorenzetti
SpoonRocket reels in top chef, and $11 million
By
Laura Lorenzetti
PeopleDoc secures $17.5 million in funding
By
Laura Lorenzetti
The Whistle scores funding, celebrity approval
By
Laura Lorenzetti
Yahoo buys ‘self-destruct’ mobile messaging app Blink
By
Laura Lorenzetti
Google shatters the Glass ceiling
By
Laura Lorenzetti
As mortgage rates fall slightly, borrowers look to refinance
By
Laura Lorenzetti
Fannie and Freddie overseer won’t slice loan limits
By
Laura Lorenzetti
Valeant ready to beef up bid for maker of Botox
By
Laura Lorenzetti
Pfizer admits to potential job losses in AstraZeneca takeover
By
Laura Lorenzetti
BSkyB looking to buy into Italian and German pay-TV markets
By
Laura Lorenzetti
AIG homes in on two homegrown execs for new CEO
By
Laura Lorenzetti
Finance
Pfizer prepares to woo U.K. lawmakers in bid for rival AstraZeneca
By
Laura Lorenzetti
Finance
Hilton sees a rosy year ahead as earnings surge
By
Laura Lorenzetti
AstraZeneca shares climb in hopes of bigger Pfizer offer
By
Laura Lorenzetti